AVI BioPharma (AVII)
AVI BioPharma Market Cap: 97.53M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
AVII Market Cap Rankings
| Overall | 23rd percentile | 3578 of 4649 |
| Sector | 30th percentile | 365 of 525 in Healthcare |
| Industry | 30th percentile | 113 of 163 in Biotechnology |
AVII Market Cap Range, Past 5 Years
| Minimum | 46.97M | Dec 2008 |
| Maximum | 242.61M | Dec 2010 |
| Average | 141.18M |
About Market Capitalization
Market Capitalization (Market Cap) is a measurement of business value based on share price and number of shares outstanding. It generally represents the market's view of a company's stock value and is a determining factor in stock valuation.
For example, if a company has 1.5 million shares outstanding at a share price of $25, its market cap is $37.5 million (1.5 million x $25). Companies can be categorized based upon the size of their market capitalization.
There are five basic groups: mega-cap (market cap over $200B), large-cap ($10B–$200B), mid-cap ($2B–$10B), small-cap ($300M–$2B), and micro-cap ($50M-$300M). Market cap is not always an accurate indication of value because it does not account for debt and other factors.
Learn More
You may also be interested in these AVII related companies
AVII News
$AVII PASSED a double bottom retest of .75 on lighter vol, I'm buying
about 12 days ago by EE551976
about 12 days ago by EE551976
Listen to $AVII Q1 2012 earnings call - live at 05:00 PM, ondemand after - http://stks.co/3mFr
about 17 days ago by earningscast
about 17 days ago by earningscast
AVI BioPharma Announces First Quarter 2012 Financial Results and Recent Corporate Developments
May 10, 4:05PM Marketwire
May 10, 4:05PM Marketwire
AVI BioPharma Announces First Quarter 2012 Financial Results and Corporate Update Conference Call
May 03, 8:30AM Marketwire
May 03, 8:30AM Marketwire
$AVII Market Watch is showing pop to .87c AH and immediate drop. http://stks.co/3dOy
about 25 days ago by abubnic
about 25 days ago by abubnic
$AVII to Present Additional Data From the Phase IIb Study of Eteplirsen at the 2012 AAN Annual Meeting
http://stks.co/3dO1
about 25 days ago by abubnic
about 25 days ago by abubnic
$AVII...Filled some this morning on the expected full data release from the Phase II dmd trial due to be released tonight or tomorrow
about 33 days ago by holiday613
about 33 days ago by holiday613
@mandkgale $AVII ive given up trying to understand. What ever stock I buy you should just short it if u want to make money...
about 40 days ago by gotgame83
about 40 days ago by gotgame83
$AVII pipeline good, positive news last review and steady drop. Good company short pressure?
about 40 days ago by mandkgale
about 40 days ago by mandkgale
@mandkgale $avii chart looks broken (falling knife) plus this is the nature of biotech. nobody wants to hold southbound stocks.
about 40 days ago by Good2go
about 40 days ago by Good2go
$AVII has anyone see any news on this and why the sudden drop with no news anywhere??
about 40 days ago by mandkgale
about 40 days ago by mandkgale
$AVII shares down ~8% as Chief Scientific Officer Peter Linsley to resign
about 45 days ago by Street_Insider
about 45 days ago by Street_Insider
$AVII Senior VP & Chief Scientific Officer to resign effective June 1. http://stks.co/3KMl
about 45 days ago by TradeHawk
about 45 days ago by TradeHawk
JMP Securities initiates $AVII with market outperform rating and $3 target
about 47 days ago by TradeHawk
about 47 days ago by TradeHawk
$AVII Personally I think at 1 dollar its extremely cheap and come monday if its still here I will be buying more
about 51 days ago by gotgame83
about 51 days ago by gotgame83
$AVII levels then it will change the way in which we understand duchenne and becker
about 51 days ago by gotgame83
about 51 days ago by gotgame83
$AVII consistent with improved results however its still to early to see the effects. If it did not produce results even with the increased
about 51 days ago by gotgame83
about 51 days ago by gotgame83
$AVII no news im aware of. Stock got hit hard bc people were expecting great results already. it signficantly increase dystrophin to levels
about 51 days ago by gotgame83
about 51 days ago by gotgame83
Wedbush Reiterates an 'Outperform' on AVI BioPharma (AVII); Sell-Off Misses Point; Higher Dose Hit Endpoint
Apr 02, 1:51PM Street Insider
Apr 02, 1:51PM Street Insider
AVI BioPharma (AVII) Slammed Following Eteplirsen Update; Shorter Duration Shows No Significant Dystrophin Increase
Apr 02, 9:27AM Street Insider
Apr 02, 9:27AM Street Insider
AVI BioPharma (AVII) Says Eteplirsen Met Primary Endpoint in DMD Following Phase IIb Trial
Apr 02, 7:04AM Street Insider
Apr 02, 7:04AM Street Insider
AVI BioPharma to Present Company Overview at the 11th Annual Needham Healthcare Conference
Mar 27, 8:30AM Marketwire
Mar 27, 8:30AM Marketwire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| AVII | 0.7185 | -0.01 | -1.58% | 97.53M |
| AVID | 6.68 | -0.11 | -1.62% | 258.45M |
| AVGO | 33.15 | +0.64 | +1.97% | 8.085B |
| AVEO | 12.60 | +0.41 | +3.36% | 544.95M |
| AVD | 25.75 | -0.01 | -0.04% | 710.96M |
| AVCA | 6.199 | +0.26 | +4.36% | 36.08M |
| AVB | 139.84 | -1.30 | -0.92% | 13.31B |
| AVAV | 21.53 | -0.11 | -0.51% | 475.81M |
| AVA | 25.45 | -0.04 | -0.16% | 1.490B |
| BAMM | 3.24 | +0.02 | +0.62% | 51.22M |
